Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal injections for diabetic macular edema and helps delay progression of ...

A funding shortfall for a key copay assistance program to help make eye injections more affordable for low-income patients has caused widespread disruption in treatment, researchers have found. The ...

Eye drop nanoparticles that shrink over time overcome the eye's natural defenses, delivering protein drugs to the retina and matching the effectiveness of direct injection in mice. (Nanowerk Spotlight ...